scientific Advisory Board
Scientific Advisory Board
Dr. James E. Sanders, DVM, PhD, DABT

Is President of New Entity Consulting, Inc. providing to clients support in regulatory toxicology. Has over thirty years experience in Toxicology and Veterinary Pathology in the pharmaceutical industry. Employed from1978 to 1981 as a staff pathologist in the U.S. Army at Walter Reed Army Institute of Research and from 1981 to 1987 as a Veterinary Pathologist at Merck, Sharp and Dohme. Joined Rhône-Poulenc Rorer as Director of Toxicology in 1987 and continued through mergers (Aventis, Sanofi Aventis) until 2005. Here, as Global Head of Toxicology, had worldwide responsibilities for designing and implementing the nonclinical toxicology and safety pharmacology testing of all drug candidates developed by the company. Was responsible for the preparation of the nonclinical sections for all INDs, NDAs, CTXs, and MAAs and for the communications with government Health Authorities globally. From 2005 to 2007 was Senior Director at Johnson & Johnson, directing development of pharmaceuticals from early development through NDA and MAA approval including government Health Authority interface. In these positions, has represented his company externally in forums and working parties such as the CPMP’s SWP, DIA, ILSI, Toxicology Forum, ICH and PhRMA. Attended Ohio State University gaining a DVM, an MS in Pharmacology and a PhD in toxicology. Is certified by the American Board of Toxicology and is a member of the SOT, and the Society of Toxicological Pathologists.

Dr. Cheryl London, DVM, PhD

Cheryl London is a Professor at the Ohio State University College of Veterinary Medicine, Department of Veterinary Biosciences. She holds the Thekla R. and Donald B. Shackelford Professorship in Canine Medicine, is Director of the Clinical Trials Office, College of Veterinary Medicine and Director of Translational Therapeutics at the Center for Clinical and Translational Sciences, OSU College of Medicine. Before coming to Ohio State in 2005, she was an Assistant Professor in the Department of Surgical and Radiological Sciences at the University of California Davis. Dr. London earned her DVM at Tufts University, completed her Residency in Medical Oncology at the University of Wisconsin-Madison, and her PhD at Harvard University, where she was also postdoctoral fellow in the Department of Pathology. Her research interests center primarily on targeted therapeutics and translational/comparative oncology.

Dr. Phillip A Haywood, Ph.D.

Phil Haywood is a consultant inhalation and intranasal product development expert. He works with several large pharmaceutical, device companies and small biotech companies assisting with their pulmonary product development programmes.Previously he was head of Inhalation and Device Development at Novartis from 2002 to 2005 responsible for all inhalation product development. He worked for 28 years at GSK in pharmaceutical and respiratory product development in increasing roles of seniority including head of respiratory analysis department, analytical research "2" department, clinical supplies department and inhalation product development UK department. He was a senior member in the GSK inhalation development departments during the CFC/HFA transition and the development of Servent, Flovent and Seretide/Advair in both MDI and DPI formats. He has also been international project team leader for Seretide/Advair and a member of the Diskus development team. In both companies he was part of or led the teams developing their key inhalation and intranasal products and sat on senior strategy and research boards. He has been a member of IPAC-RS and now serves on the DDL organising committee. He obtained his PhD via CNAA through the University of Hertford and his BSc from the University of London.

Dr. T. S. Ganesan M.D, Ph.D

Dr. T.S.Ganesan graduated 'Summa cum Laude' from Jawaharlal Institute of Medical Education and Research, Pondicherry, India and completed his MBBS and MD in Internal medicine followed by Senior Residency. He completed his training in Medical Oncology at St. Bartholomew's Hospital, London. His doctorate was on Philadelphia chromosome positive leukemias that was awarded by the University of London. He was subsequently appointed as Consultant Medical Oncologist at Churchill Hospital, Oxford and established a laboratory as Clinical Scientist at the Weatherall Institute of Molecular Medicine, Oxford. After 15 years at Oxford he was appointed as Chairman, Cancer Institute and Institute of Molecular Medicine at Amrita Institute of Medical Sciences, Cochin, India towards the end of 2005. His research interests have been on cancer genetics and signal transduction, in addition to clinical trials. The research in UK was supported initially by the Imperial Cancer Research Fund and subsequently by Cancer Research UK. In India, the research is supported by Department of Biotechnology and Indian Council of Medical Research. He has been awarded the Clinical Excellence award in UK during his tenure there. He has over 100 papers to his credit in international journals.

Dr. Dhanapalan Nagarathnam Ph.D

Dr. Nagarathnam is currently the President of DNSK International, llc. Hamden, CT, where he is focused on collaborative drug discovery projects with biotechs and leading academic institutions in a variety of therapeutic areas including multiple cancer indications, diabetes, autoimmune disorders, HCV, anti-bacterial, inflammatory bowel disease (IBD), etc. Prior to this, Dr. Nagarathnam was the Director of Medicinal Chemistry at Pharmasset, Princeton, NJ, wherein he directed the HCV drug discovery projects and played a key role in selecting three liver-targeted clinical candidates and the most advanced candidate is in Phase-III human trials, and the company was later acquired by Gilead in 2012. Dr. Nagarathnam also worked as Principal Research Scientist-II at Bayer HealthCare, West Haven, CT, in multiple oncology, diabetes, obesity and osteoporosis projects and Synaptic Pharmaceutical Corporation (currently Lundbeck), Paramus, NJ on multiple human GPCR-targeted projects targeting BPH, pain, obesity, etc. In the Synaptic/Merck collaboration project he contributed to nomination of two alpha-1a adrenoceptor selective candidates for the treatment of Benign Prostatic Hyperplasia (BPH).

Dr. Nagarathnam has over 25 years of experience in pharmaceutical industry and this includes leadership role in project management, medicinal chemistry, combinatorial chemistry, high-throughput synthesis, lead generation, lead optimization, process research, production, and business development.

Dr. Nagarathnam obtained his Ph. D. in Organic Chemistry from the University of Madras, India and conducted postdoctoral research in Medicinal Chemistry at University of California, Purdue University, and University of Illinois and process research at Malti-Chem Research Center. Overall, Nagarathnam is an inventor on over 50 issued patents/patent applications, and an author of over 75 peer-reviewed publications in leading journals and conference presentations

Dr. Douglas W.P. Hay, Ph.D

Dr. Douglas W.P. Hay obtained his Ph.D. in Physiology and Pharmacology from the University of Strathclyde, Scotland. Douglas is a Pharmaceutical Executive with more than 20 years experience in Drug Discovery, with particular expertise in respiratory and inflammatory disease therapeutic areas. Douglas joined GSK in 1985, and from 2001-2007 he was Vice President of the Chronic Obstructive Pulmonary Disease (COPD) Drug Discovery group within the Respiratory & Inflammation Centre of Excellence for Drug Discovery, leading over 80 staff. From 1985-2007 at GSK Douglas and staff identified more than 25 compounds selected for development, with 1 NDA filed and 1 compound completing Phase III clinical trials. In 2007 Douglas joined Galleon Pharmaceuticals, a start-up company in Horsham, PA, as Senior Vice President, Drug Discovery, where in less than 6 months he built a high-quality team working on medicines for ventilatory control conditions, such as sleep apnea. Douglas is recognized internationally as an expert in the area of respiratory science and therapeutics. He is author of over 100 peer-reviewed papers, more than 40 book chapters and reviews, and co-edited 2 books. Douglas is currently President of Hay Drug Discovery Consulting, LLC, which he formed in September, 2009.